semaglutide and low platelets GLP-1 Agents Showed Broader Risks, Rewards in 2025 Semaglutide: a key medication for

7 Expression of Ramp1 across DVC neuronal cell populations

The best semaglutide for weight loss is Wegovy, as it is FDA-approved specifically for this purpose and shown to help people with obesity lose more weight than other types

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

When Medicaid Does Cover Weight Loss Shots Even in states with limited obesity drug coverage, you may still qualify for a GLP-1 shot through Medicaid if you meet any of these conditions: You have Type 2 diabetes

A better understanding of the microbiome-immune system interactions will help us develop more targeted, specific antitumor medications in the future

Metabolic acidosis in the critically ill: part 1